Every Form 4 that Galecto, Inc. (GLTO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GLTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GLTO filings page.
Damora Therapeutics director and officer Jennifer Jarrett received new equity awards as compensation. On March 30, 2026, she was granted stock options to purchase 1,500,000 shares of common stock at an exercise price of $25.50 per share, expiring March 30, 2036. The options vest 25% on March 30, 2027 and then in equal monthly installments through March 30, 2030, subject to continued service. She also received 500,000 restricted stock units, each representing one share of common stock, vesting 25% on each anniversary of the grant date over four years, also conditioned on continued service. Following these awards, she directly holds 500,000 shares of common stock and 1,500,000 options.
Damora Therapeutics, Inc. director Turtle Cameron received a grant of stock options covering 37,313 shares of common stock. The options carry an exercise price of $23.05 per share and expire on March 23, 2036.
The award vests in equal monthly installments through March 23, 2029, as long as Cameron continues to provide service to the company. Following this grant, Cameron holds stock options for 37,313 underlying shares directly, reflecting a compensation-related equity award rather than an open-market share purchase or sale.
Damora Therapeutics director Michael Landsittel received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share and expires on March 23, 2036. It vests in equal monthly installments through March 23, 2029, contingent on his continued service. Following this grant, he holds options for 37,313 shares directly.
Damora Therapeutics, Inc. reported that director Christopher W. Cain was granted a stock option covering 37,313 shares of common stock at an exercise price of $23.05 per share. The option expires on March 23, 2036 and vests in equal monthly installments through March 23, 2029, conditioned on his continued service.
According to the disclosure, Cain holds this option for one or more investment vehicles managed by Fairmount Funds Management LLC, is required to turn over any net cash or stock from the option to Fairmount, and therefore disclaims beneficial ownership of both the option and the underlying shares. Fairmount also disclaims beneficial ownership except to the extent of its pecuniary interest.
Damora Therapeutics director Bruno Julianne received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share, carries no upfront cost, and will vest in equal monthly installments through March 23, 2029, conditioned on continued service. Following this award, Julianne holds options for 37,313 underlying shares directly.
Galecto, Inc. director Bruno Julianne reported acquiring Common Stock through the conversion of preferred shares. On February 9, 2026, after stockholders approved the issuance of Common Stock upon conversion of Series C Non-Voting Convertible Preferred Stock, 129 shares of Series C Preferred Stock converted into 129,000 shares of Common Stock at a price of $0 per share.
After this derivative conversion, Julianne directly beneficially owned 137,032 shares of Common Stock. These securities, including the newly issued Common Stock, are subject to a lock-up agreement related to Galecto’s public offering, restricting sales or transfers for 60 days following the February 10, 2026 final prospectus supplement.
Galecto, Inc. reported that investment funds managed by Fairmount converted Series C Non-Voting Convertible Preferred Stock into common shares after stockholder approval on February 9, 2026. Fairmount Healthcare Fund II L.P. converted 5,809 Series C shares into 5,809,000 common shares, and Fairmount Healthcare Co-Invest V L.P. converted 2,904 Series C shares into 2,904,000 common shares, reflecting a 1,000-to-1 conversion ratio.
The converted shares, along with other securities held by the reporting persons, are subject to a lock-up that generally restricts sales or transfers for 60 days after the February 10, 2026 final prospectus supplement for Galecto’s public offering. The Series C Preferred Stock has no expiration date, and conversions are capped so that Fairmount and its affiliates cannot beneficially own more than 19.99% of Galecto’s outstanding common shares immediately after any conversion. Fairmount Funds Management LLC, led by managers Peter Harwin and Tomas Kiselak, is the investment manager for the converting funds and disclaims beneficial ownership except for its pecuniary interest.
Galecto, Inc. reported new equity awards to its Chief Operating Officer, Sherwin Sattarzadeh. On January 5, 2026, he received 190,376 shares of common stock in the form of restricted stock units, granted at a price of $0 per share. These RSUs vest 25% on each anniversary of the grant date over four years, so the award is spread out to encourage continued service.
On the same date, he was also granted a stock option covering 444,209 shares of common stock with an exercise price of $21.82 per share. This option vests 25% on January 5, 2027 and then in equal monthly installments through January 5, 2030, again conditioned on his continued service to Galecto.
Galecto, Inc. reported new equity awards to Chief Medical Officer Hewes L. Becker. On January 5, 2026, Becker received 264,629 restricted stock units, each representing one share of Galecto common stock at settlement. These RSUs vest 25% on each anniversary of the grant date over four years, conditioned on continued service.
On the same date, Becker was granted a stock option covering 528,603 shares of common stock at an exercise price of $21.82 per share. The option vests 25% on January 5, 2027 and then in equal monthly installments through January 5, 2030, also subject to continued service. Following these grants, Becker directly holds 264,629 shares of common stock and options for 528,603 shares.